Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6420689 | 0.88 | SLC2A1 (0.34) | CHRM2CHRM4CHRM1CHRM3SLC2A1 | |
| SCHEMBL22282309 | 0.84 | CHRM2 (0.32) | CHRM2CHRM4CHRM1CHRM3SLC2A1 | |
| SCHEMBL31069932 | 0.83 | SLC2A1 (0.32) | CHRM2CHRM4CHRM1CHRM3SLC2A1 | |
| SCHEMBL950901 | 0.80 | SLC2A1 (0.37) | CHRM2CHRM4CHRM1CHRM3SLC2A1 | |
| SCHEMBL25840249 | 0.78 | PLA2G1B (0.37) | SLC2A1MGLL | |
| SCHEMBL913401 | 0.78 | — | — | |
| SCHEMBL9557913 | 0.75 | — | — | |
| SCHEMBL5002428 | 0.75 | MEN1 (0.34) | CHRM2CHRM4CHRM1CHRM3SLC2A1 | |
| SCHEMBL5028953 | 0.75 | — | — | |
| SCHEMBL31069963 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989263-B1 | Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-01-24 | — | — | US | claimed |
| US-20030198648-A1 | Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to HIV-1 RNA | ACHILION PHARMACEUTICALS | 2003-10-23 | — | — | US | claimed |
| WO-2003060098-A2 | METHODS FOR IDENTIFYING COMPOUNDS WHICH INHIBIT BINDING OF NUCLEOCAPSID 7 PROTEIN TO HIV-1 RNA | ACHILLION PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | WO | claimed |
| EP-0782632-B1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | US GOV HEALTH & HUMAN SERV (US) | 2003-04-16 | — | — | EP | claimed |
| US-6001555-A | DISSOCIATING A ZINC FINGER BY CONTACTING THE PROTEIN WITH A DISULFIDE, A MALEIMIDE, AN ALPHA-HALOGENATED KETONE, A HYDRAZIDE, A NITRIC OXIDE OR DERIVATIVES, CUPRIC IONS, FERRIC IONS OR THEIR COMPLEXES; SYNERGISTIC EFFECTS WITH VIRICIDES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-14 | — | — | US | claimed |
| WO-1996009406-A1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-03-28 | — | — | WO | claimed |
| US-20220119662-A1 | RADIATION CURABLE INKJET INKS FOR INTERIOR DECORATION | AGFA NV (BE) | 2022-04-21 | — | — | US | disclosed |
| EP-3686252-A1 | RADIATION CURABLE INKJET INK FOR MANUFACTURING PRINTED CIRCUIT BOARDS | AGFA-GEVAERT NV (BE) | 2020-07-29 | — | — | EP | disclosed |
| US-20160052972-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. | 2016-02-25 | — | — | US | disclosed |
| US-20160052972-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. | 2016-02-25 | — | — | US | disclosed |
| US-20160052972-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. | 2016-02-25 | — | — | US | disclosed |
| US-9217015-B2 | Cyclosporin derivatives for the treatment and prevention of a viral infection | S&T GLOBAL INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-9217015-B2 | Cyclosporin derivatives for the treatment and prevention of a viral infection | S&T GLOBAL INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20030092763-A1 | Method for induction of L-selectin shedding | SCIENCE & TECHNOLOGY CORPORATION @UNM | 2003-05-15 | — | — | US | disclosed |
| EP-0782632-B1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | US GOV HEALTH & HUMAN SERV (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6498189-B1 | SUPPRESSION OF INFLAMMATION AND OF LYMPH NODE ENTRY BY CALMODULIN ANTAGONISTS; CELL ASSOCIATED PROTEIN DISULFIDE ISOMERASE INHIBITORS; P-AMINOPHENYLARSINE OXIDES | UNIVERSITY OF NEW MEXICO | 2002-12-24 | — | — | US | disclosed |
| US-6316190-B1 | FOR DETECTING OR PURIFYING HUMAN IMMUNODEFICIENCY VIRUS(HIV) FROM BLOOD SAMPLE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-11-13 | — | — | US | disclosed |
| US-6001555-A | DISSOCIATING A ZINC FINGER BY CONTACTING THE PROTEIN WITH A DISULFIDE, A MALEIMIDE, AN ALPHA-HALOGENATED KETONE, A HYDRAZIDE, A NITRIC OXIDE OR DERIVATIVES, CUPRIC IONS, FERRIC IONS OR THEIR COMPLEXES; SYNERGISTIC EFFECTS WITH VIRICIDES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-14 | — | — | US | disclosed |
| US-5965527-A | CYCLOSPORIN A SULFIDED AT THE 3 POSITION BY R-(CH)N-S-BY REACTING A LITHIUM-ACTIVATED DERIVATIVE WITH THE DISULFIDE; SYNERGISTIC MIXTURE WITH A RETROVIRUS VIRICIDE; SIDE-EFFECT REDUCTION; AIDS AND ARC (AIDS RELATED COMPLEX) | RHONE-POULENC RORER, S.A. (FR) | 1999-10-12 | — | — | US | disclosed |
| WO-1996009406-A1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052972-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | HAVCR2, TSLP, ICOS | CHRM2 4645/4885CHRM4 4605/4885CHRM1 4675/4885 |
| US-20030198648-A1 | Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to HIV-1 RNA | MRPS27, SNRPE, NSUN2 | CHRM2 4714/4885CHRM4 3843/4885CHRM1 4511/4885 |
| US-20030092763-A1 | Method for induction of L-selectin shedding | PDIA5, PDIA4, PDIA6 | CHRM2 3821/4885CHRM4 3112/4885CHRM1 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.